Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30922283 | 0.80 | IKZF1 (0.55) | DDB1CRBNIKZF2IKZF1DRD2 | |
| SCHEMBL23117767 | 0.76 | CRBN (0.55) | DDB1CRBNIKZF1PARP1 | |
| SCHEMBL23115246 | 0.75 | CRBN (0.46) | DDB1CRBN | |
| SCHEMBL31426245 | 0.74 | DDB1 (0.58) | DDB1CRBN | |
| SCHEMBL23115216 | 0.74 | DDB1 (0.58) | DDB1CRBN | |
| SCHEMBL23115214 | 0.74 | DDB1 (0.58) | DDB1CRBN | |
| SCHEMBL23115215 | 0.74 | DDB1 (0.58) | DDB1CRBN | |
| SCHEMBL31454804 | 0.74 | IKZF2 (0.51) | DDB1CRBNIKZF2IKZF1DRD2 | |
| SCHEMBL24938771 | 0.73 | CRBN (0.44) | DDB1CRBN | |
| SCHEMBL24950299 | 0.73 | CRBN (0.47) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4626880-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | Shanghai Degron Biomedical Technology Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024114639-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | ELAVL1, ELAVL3, HNRNPL | DDB1 568/4885CRBN 1001/4885IKZF2 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.